1型黄斑毛细血管扩张伴黄斑水肿患者抗血管内皮生长因子治疗前后黄斑血流密度的变化

Q4 Medicine

中华眼底病杂志 Pub Date : 2020-01-25 DOI:10.3760/CMA.J.ISSN.1005-1015.2020.01.003

Yue Zhao, Y. Qi, Mudi Yao

{"title":"1型黄斑毛细血管扩张伴黄斑水肿患者抗血管内皮生长因子治疗前后黄斑血流密度的变化","authors":"Yue Zhao, Y. Qi, Mudi Yao","doi":"10.3760/CMA.J.ISSN.1005-1015.2020.01.003","DOIUrl":null,"url":null,"abstract":"Objective \nTo observe the changes of macular blood flow density in patients of macular telangiectasis type 1 (Mac-Tel type 1) with macular edema before and after the treatment of anti-VEGF. \n \n \nMethods \nA retrospective clinical study. From January 2016 to December 2017, 14 Mac-Tel type 1 patients (14 eyes) diagnosed in Nanjing Medical University Eye Hospital were included in the study. There were 6 males (6 eyes) and 8 females (8 eyes), with the mean age of 35.3±9.3 years. All patients underwent BCVA and OCT angiography examinations. The BCVA examination was performed using the Snellen visual acuity chart, which was converted into logMAR visual acuity. All the patients were received anti-VEGF injection treatment once a month for 3 consecutive months. The OCTA scanning region in the macular area was 3 mm × 3 mm. Macular blood flow density in the superficial capillary plexus (SCP) and deep capillary plexus (DCP), the vessel density within a 300 μm width ring surrounding the foveal avascular area (FD-300) and central macular thickness (CMT) were measured in all eyes. Paired samples t-test and Pearson correlation analysis were used in this study. \n \n \nResults \nAt the baseline, logMAR BCVA was 0.69±0.07, CMT was 468.43±26.59 μm, SCP blood flow density was (50.99±1.19)%, DCP blood flow density was (43.79±1.44)%, FD-300 was (50.73±1.16)%. Compared with the baseline, there were significant differences between logMAR BCVA, CMT, DCP blood flow density and FD-300 in 1 week, 1 month, 3 months after treatment and 2 months after cessation of treatment (logMAR BCVA: t=6.77, 13.30, 16.99, 9.51; P=0.00, 0.01, 0.00, 0.01. CMT: t=6.99, 15.88, 26.10, 6.50; P=0.00, 0.01, 0.01, 0.00. DCP: t=6.75, 8.61, 15.12, 7.63; P=0.00, 0.01, 0.01, 0.00. FD-300: t=11.86, 13.08, 14.36, 4.41; P=0.00, 0.01, 0.01, 0.03). There was no significant difference in blood flow density of SCP between baseline and 2 months after cessation of treatment (t=1.36, P=0.19), but there was significant difference at the other time points after treatment (t=5.50, 6.84, 6.27; P=0.00, 0.01, 0.01). The Pearson's correlation analysis showed that there was a significant positive correlation between FD-300 and CMT (r2=0.54, P=0.04). \n \n \nConclusions \nThere is no significant change in the SCP blood flow density in the patients of Mac-Tel type 1 with macular edema, while the DCP blood flow density decreased and FD-300 increased. After anti-VEGF treatment, DCP blood flow density increased and FD-300 decreased. FD-300 is positively correlated with CMT. \n \n \nKey words: \nRegional blood flow; Telangiectasis; Macular edema; Angiogenesis inhibitors/therapeutic use; Tomography, optical coherence","PeriodicalId":10103,"journal":{"name":"中华眼底病杂志","volume":"36 1","pages":"10-14"},"PeriodicalIF":0.0000,"publicationDate":"2020-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The changes of macular blood flow density in patients of macular telangiectasis type 1 with macular edema before and after the treatment of anti-vascular endothelial growth factor\",\"authors\":\"Yue Zhao, Y. Qi, Mudi Yao\",\"doi\":\"10.3760/CMA.J.ISSN.1005-1015.2020.01.003\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Objective \\nTo observe the changes of macular blood flow density in patients of macular telangiectasis type 1 (Mac-Tel type 1) with macular edema before and after the treatment of anti-VEGF. \\n \\n \\nMethods \\nA retrospective clinical study. From January 2016 to December 2017, 14 Mac-Tel type 1 patients (14 eyes) diagnosed in Nanjing Medical University Eye Hospital were included in the study. There were 6 males (6 eyes) and 8 females (8 eyes), with the mean age of 35.3±9.3 years. All patients underwent BCVA and OCT angiography examinations. The BCVA examination was performed using the Snellen visual acuity chart, which was converted into logMAR visual acuity. All the patients were received anti-VEGF injection treatment once a month for 3 consecutive months. The OCTA scanning region in the macular area was 3 mm × 3 mm. Macular blood flow density in the superficial capillary plexus (SCP) and deep capillary plexus (DCP), the vessel density within a 300 μm width ring surrounding the foveal avascular area (FD-300) and central macular thickness (CMT) were measured in all eyes. Paired samples t-test and Pearson correlation analysis were used in this study. \\n \\n \\nResults \\nAt the baseline, logMAR BCVA was 0.69±0.07, CMT was 468.43±26.59 μm, SCP blood flow density was (50.99±1.19)%, DCP blood flow density was (43.79±1.44)%, FD-300 was (50.73±1.16)%. Compared with the baseline, there were significant differences between logMAR BCVA, CMT, DCP blood flow density and FD-300 in 1 week, 1 month, 3 months after treatment and 2 months after cessation of treatment (logMAR BCVA: t=6.77, 13.30, 16.99, 9.51; P=0.00, 0.01, 0.00, 0.01. CMT: t=6.99, 15.88, 26.10, 6.50; P=0.00, 0.01, 0.01, 0.00. DCP: t=6.75, 8.61, 15.12, 7.63; P=0.00, 0.01, 0.01, 0.00. FD-300: t=11.86, 13.08, 14.36, 4.41; P=0.00, 0.01, 0.01, 0.03). There was no significant difference in blood flow density of SCP between baseline and 2 months after cessation of treatment (t=1.36, P=0.19), but there was significant difference at the other time points after treatment (t=5.50, 6.84, 6.27; P=0.00, 0.01, 0.01). The Pearson's correlation analysis showed that there was a significant positive correlation between FD-300 and CMT (r2=0.54, P=0.04). \\n \\n \\nConclusions \\nThere is no significant change in the SCP blood flow density in the patients of Mac-Tel type 1 with macular edema, while the DCP blood flow density decreased and FD-300 increased. After anti-VEGF treatment, DCP blood flow density increased and FD-300 decreased. FD-300 is positively correlated with CMT. \\n \\n \\nKey words: \\nRegional blood flow; Telangiectasis; Macular edema; Angiogenesis inhibitors/therapeutic use; Tomography, optical coherence\",\"PeriodicalId\":10103,\"journal\":{\"name\":\"中华眼底病杂志\",\"volume\":\"36 1\",\"pages\":\"10-14\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-01-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"中华眼底病杂志\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3760/CMA.J.ISSN.1005-1015.2020.01.003\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"中华眼底病杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1005-1015.2020.01.003","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

目的观察黄斑毛细血管扩张1型(Mac-Tel 1型)伴黄斑水肿患者抗vegf治疗前后黄斑血流密度的变化。方法回顾性临床研究。选取2016年1月至2017年12月在南京医科大学眼科医院确诊的14例Mac-Tel 1型患者(14只眼)纳入研究。男性6只(6眼)，女性8只(8眼)，平均年龄35.3±9.3岁。所有患者均行BCVA和OCT血管造影检查。BCVA检查采用Snellen视度表进行，视度表转换为logMAR视力。所有患者均接受抗vegf注射治疗，每月1次，连续3个月。黄斑区OCTA扫描面积为3mm × 3mm。测量各组黄斑浅毛细血管丛(SCP)和深毛细血管丛(DCP)血流密度、中央凹无血管区周围300 μm宽环内血管密度(FD-300)和黄斑中心厚度(CMT)。本研究采用配对样本t检验和Pearson相关分析。结果基线时logMAR BCVA为0.69±0.07,CMT为468.43±26.59 μm, SCP血流量密度为(50.99±1.19)%，DCP血流量密度为(43.79±1.44)%，FD-300为(50.73±1.16)%。与基线比较，治疗后1周、1个月、3个月和停药后2个月logMAR BCVA、CMT、DCP血流量密度和FD-300差异均有统计学意义(logMAR BCVA: t=6.77、13.30、16.99、9.51;P=0.00, 0.01, 0.00, 0.01。CMT: t=6.99, 15.88, 26.10, 6.50;P=0.00, 0.01, 0.01, 0.00。DCP: t=6.75, 8.61, 15.12, 7.63;P=0.00, 0.01, 0.01, 0.00。FD-300: t=11.86, 13.08, 14.36, 4.41;P=0.00, 0.01, 0.01, 0.03)。停药后2个月与基线间SCP血流密度差异无统计学意义(t=1.36, P=0.19)，治疗后其他时间点间SCP血流密度差异有统计学意义(t=5.50, 6.84, 6.27;P=0.00, 0.01, 0.01)。Pearson相关分析显示FD-300与CMT呈显著正相关(r2=0.54, P=0.04)。结论Mac-Tel 1型伴黄斑水肿患者SCP血流密度无明显变化，DCP血流密度降低，FD-300升高。抗vegf治疗后，DCP血流密度升高，FD-300降低。FD-300与CMT呈正相关。关键词:局部血流;毛细管扩张;黄斑水肿;血管生成抑制剂/治疗用途;层析成像，光学相干

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

The changes of macular blood flow density in patients of macular telangiectasis type 1 with macular edema before and after the treatment of anti-vascular endothelial growth factor

Objective To observe the changes of macular blood flow density in patients of macular telangiectasis type 1 (Mac-Tel type 1) with macular edema before and after the treatment of anti-VEGF. Methods A retrospective clinical study. From January 2016 to December 2017, 14 Mac-Tel type 1 patients (14 eyes) diagnosed in Nanjing Medical University Eye Hospital were included in the study. There were 6 males (6 eyes) and 8 females (8 eyes), with the mean age of 35.3±9.3 years. All patients underwent BCVA and OCT angiography examinations. The BCVA examination was performed using the Snellen visual acuity chart, which was converted into logMAR visual acuity. All the patients were received anti-VEGF injection treatment once a month for 3 consecutive months. The OCTA scanning region in the macular area was 3 mm × 3 mm. Macular blood flow density in the superficial capillary plexus (SCP) and deep capillary plexus (DCP), the vessel density within a 300 μm width ring surrounding the foveal avascular area (FD-300) and central macular thickness (CMT) were measured in all eyes. Paired samples t-test and Pearson correlation analysis were used in this study. Results At the baseline, logMAR BCVA was 0.69±0.07, CMT was 468.43±26.59 μm, SCP blood flow density was (50.99±1.19)%, DCP blood flow density was (43.79±1.44)%, FD-300 was (50.73±1.16)%. Compared with the baseline, there were significant differences between logMAR BCVA, CMT, DCP blood flow density and FD-300 in 1 week, 1 month, 3 months after treatment and 2 months after cessation of treatment (logMAR BCVA: t=6.77, 13.30, 16.99, 9.51; P=0.00, 0.01, 0.00, 0.01. CMT: t=6.99, 15.88, 26.10, 6.50; P=0.00, 0.01, 0.01, 0.00. DCP: t=6.75, 8.61, 15.12, 7.63; P=0.00, 0.01, 0.01, 0.00. FD-300: t=11.86, 13.08, 14.36, 4.41; P=0.00, 0.01, 0.01, 0.03). There was no significant difference in blood flow density of SCP between baseline and 2 months after cessation of treatment (t=1.36, P=0.19), but there was significant difference at the other time points after treatment (t=5.50, 6.84, 6.27; P=0.00, 0.01, 0.01). The Pearson's correlation analysis showed that there was a significant positive correlation between FD-300 and CMT (r2=0.54, P=0.04). Conclusions There is no significant change in the SCP blood flow density in the patients of Mac-Tel type 1 with macular edema, while the DCP blood flow density decreased and FD-300 increased. After anti-VEGF treatment, DCP blood flow density increased and FD-300 decreased. FD-300 is positively correlated with CMT. Key words: Regional blood flow; Telangiectasis; Macular edema; Angiogenesis inhibitors/therapeutic use; Tomography, optical coherence

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

中华眼底病杂志 Medicine-Ophthalmology

CiteScore

0.40

自引率

0.00%

发文量

5383

期刊介绍： Chinese Journal of Ocular Fundus Diseases is the only scientific journal in my country that focuses on reporting fundus diseases. Its purpose is to combine clinical and basic research, and to give equal importance to improvement and popularization. It comprehensively reflects the leading clinical and basic research results of fundus disease disciplines in my country; cultivates professional talents in fundus disease, promotes the development of fundus disease disciplines in my country; and promotes academic exchanges on fundus disease at home and abroad. The coverage includes clinical and basic research results of posterior segment diseases such as retina, uveal tract, vitreous body, visual pathway, and internal eye diseases related to systemic diseases. The readers are medical workers and researchers related to clinical and basic research of fundus diseases. According to the journal retrieval report of the Chinese Institute of Scientific and Technological Information, the comprehensive ranking impact factor and total citation frequency of the Chinese Journal of Ocular Fundus Diseases have been among the best in the disciplines of ophthalmology, otolaryngology, and ophthalmology in my country for many years. The papers published have been included in many important databases at home and abroad, such as Scopus, Peking University Core, and China Science Citation Database (CSCD).